TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Myriad Genetics ( (MYGN) ) has shared an announcement.
On September 29, 2025, Myriad Genetics announced the resignation of Natalie Munk, their Senior Vice President and Chief Accounting Officer, effective October 24, 2025. Her departure was not due to any disagreements with the company. In response, the company appointed Benjamin R. Wheeler, their current Chief Financial Officer, as the new principal accounting officer effective upon Munk’s departure. Wheeler, who has been with the company for over thirteen years in various financial roles, will not receive additional compensation for this new designation.
The most recent analyst rating on (MYGN) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on Myriad Genetics stock, see the MYGN Stock Forecast page.
Spark’s Take on MYGN Stock
According to Spark, TipRanks’ AI Analyst, MYGN is a Neutral.
Myriad Genetics’ overall stock score reflects strong revenue growth and positive earnings call sentiment. However, significant challenges in profitability, cash flow management, and valuation weigh heavily on the score. The technical analysis shows short-term strength, but longer-term indicators suggest caution.
To see Spark’s full report on MYGN stock, click here.
More about Myriad Genetics
Average Trading Volume: 1,743,013
Technical Sentiment Signal: Sell
Current Market Cap: $703.4M
For an in-depth examination of MYGN stock, go to TipRanks’ Overview page.